Yohimbine Inhibits PDGF-Induced Vascular Smooth Muscle Cell Proliferation and Migration via FOXO3a Factor
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25136899 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Leejin Lim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Cancer Controlling Research Center, Chosun University, Gwangju 61452, Republic of Korea. Hauptthemen laut MEDLINE: Muscle, Smooth, Vascular, Forkhead Box Protein O3, Cell Proliferation, Cell Movement. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Chosun University, Ministry of Science and ICT.
Abstract (Originalsprache)
Yohimbine (YHB) has been reported to possess anti-inflammatory, anticancer, and cardiac function-enhancing properties. Additionally, it has been reported to inhibit the proliferation, migration, and neointimal formation of vascular smooth muscle cells (VSMCs) induced by platelet-derived growth factor (PDGF) stimulation by suppressing the phospholipase C-gamma 1 pathway. However, the transcriptional regulatory mechanism of YHB controlling the behavior of VSMCs is not fully understood. In this study, YHB downregulated the expression of cell cycle regulatory proteins, such as proliferating cell nuclear antigen (PCNA), cyclin D1, cyclin-dependent kinase 4 (CDK4), and cyclin E, by modulating the transcription factor FOXO3a in VSMCs induced by PDGF. Furthermore, YHB decreased p-38 and mTOR phosphorylation in a dose-dependent manner. Notably, YHB significantly reduced the phosphorylation at Y397 and Y925 sites of focal adhesion kinase (FAK), and this effect was greater at the Y925 site than Y397. In addition, the expression of paxillin, a FAK-associated protein known to bind to the Y925 site of FAK, was significantly reduced by YHB treatment in a dose-dependent manner. A pronounced reduction in the migration and proliferation of VSMCs was observed following co-treatment of YHB with mTOR or p38 inhibitors. In conclusion, this study shows that YHB inhibits the PDGF-induced proliferation and migration of VSMCs by regulating the transcription factor FOXO3a and the mTOR/p38/FAK signaling pathway. Therefore, YHB may be a potential therapeutic candidate for preventing and treating cardiovascular diseases such as atherosclerosis and vascular restenosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Advanced Cancer Controlling Research Center, Chosun University, Gwangju 61452, Republic of Korea.
- Department of Biomedical Sciences, Chosun University Graduate School, Gwangju 61452, Republic of Korea.
- Institute of Human Behavior & Genetics, Biomedical Research Center, Korea University, Seoul 02841, Republic of Korea.
- Department of Paramedicine, Nambu University, Gwangju 62271, Republic of Korea.
- Department of Biochemistry and Molecular Biology, Chosun University School of Medicine, Gwangju 61452, Republic of Korea.
ORCID-Profile: Young-Bob Yu, Heesang Song
Förderung
- National Research Foundation of Korea
- Chosun University
- Ministry of Science and ICT
Zitieren
APA
Lim, L., Kim, H., Jeong, J., Han, S. H., Yu, Y. B., & Song, H. (2024). Yohimbine Inhibits PDGF-Induced Vascular Smooth Muscle Cell Proliferation and Migration via FOXO3a Factor. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25136899
Vancouver
Lim L, Kim H, Jeong J, Han SH, Yu YB, Song H. Yohimbine Inhibits PDGF-Induced Vascular Smooth Muscle Cell Proliferation and Migration via FOXO3a Factor. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25136899
BibTeX
@article{Lim2024,
author = {Lim, Leejin and Kim, Hyeonhwa and Jeong, Jihye and Han, Sung Hee and Yu, Young-Bob and Song, Heesang},
title = {Yohimbine Inhibits PDGF-Induced Vascular Smooth Muscle Cell Proliferation and Migration via FOXO3a Factor},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25136899}
}
EUVIMED